Cargando…
Attenuated Dengue virus PV001-DV induces oncolytic tumor cell death and potent immune responses
BACKGROUND: Viral therapies developed for cancer treatment have classically prioritized direct oncolytic effects over their immune activating properties. However, recent clinical insights have challenged this longstanding prioritization and have shifted the focus to more immune-based mechanisms. Thr...
Autores principales: | Goldufsky, Josef W., Daniels, Preston, Williams, Michael D., Gupta, Kajal, Lyday, Bruce, Chen, Tony, Singh, Geeta, Kaufman, Howard L., Zloza, Andrew, Marzo, Amanda L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10357599/ https://www.ncbi.nlm.nih.gov/pubmed/37468934 http://dx.doi.org/10.1186/s12967-023-04344-8 |
Ejemplares similares
-
Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2015) -
Erratum: Oncolytic viruses: a new class of immunotherapy drugs
por: Kaufman, Howard L., et al.
Publicado: (2016) -
Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma
por: Bommareddy, Praveen K., et al.
Publicado: (2019) -
Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice
por: Zheng, Xiaoyan, et al.
Publicado: (2017) -
Practical DV filmmaking
por: Evans, Russell
Publicado: (2013)